Skip to main content
SpringerLink
Log in

Rationale and Strategies for Antiretroviral Therapy in HIV-1 Infection

  • Chapter
Book cover Atlas of AIDS

  • 99 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fauci AS: Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 1993, 262:1011–1018.

    Article  PubMed  CAS  Google Scholar 

  2. Holodny M, Katzenstein DA, Sengupta S, et al.: Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis 1991, 163:862–866.

    Article  Google Scholar 

  3. Kievits T, van Gemen B, van Strijp D, et al.: NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods 1991, 35:273–286.

    Article  PubMed  CAS  Google Scholar 

  4. Cao Y, Ho DD, Todd J, et al.: Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses 1995, 11:353–361.

    Article  PubMed  CAS  Google Scholar 

  5. Saag MS, Holodny M, Kuritzkes DR, et al.: HIV viral load markers in clinical practice. Nature Med 1996, 2:625–629.

    Article  PubMed  CAS  Google Scholar 

  6. Mellors J, Rinaldo CR Jr, Gupta P, et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167–270.

    Article  PubMed  CAS  Google Scholar 

  7. Mellors J, Kingsley LA, Rinaldo CR Jr, et al.: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573–579.

    Article  PubMed  CAS  Google Scholar 

  8. O’Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426–431.

    Article  PubMed  Google Scholar 

  9. Coombs RW, Welles SL, Hooper C, et al.: Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996, in press.

    Google Scholar 

  10. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117–122.

    Article  PubMed  CAS  Google Scholar 

  11. Ho DD, Neumann AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4+ lymphocytes in HIV-1 infection. Nature 1995, 373:123–126.

    Article  PubMed  CAS  Google Scholar 

  12. Perelson AS, Neumann AU, Markowitz M, et al.: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582–1586.

    Article  PubMed  CAS  Google Scholar 

  13. US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998; 47 (RR-5): 42–82., Available at: http://www.hivatis.org/guide-lines/adult. Update, January 28, 2000

  14. Cao Y, Qin L, Zhang L, et al.: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Eng J Med 1995, 332(4):201–208.

    Article  CAS  Google Scholar 

  15. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Eng J Med 1995, 332(4):209–216.

    Article  CAS  Google Scholar 

  16. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-fetal transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173–1180.

    Article  PubMed  CAS  Google Scholar 

  17. Guay LA, Musoke P, Fleming T, et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999, 354:795–802.

    PubMed  CAS  Google Scholar 

  18. Kinloch-de Loes S, Hirschel BJ, Hoen B, et al.: Zidovudine versus placebo in primary HIV infection: A randomized study. N Engl J Med 1995, 333:408–413.

    Article  Google Scholar 

  19. Rosenberg, ES, Billingsley JM, Caliendo AM, et al.: Vigorous HIV-1 specific CD+4 T cell responses Associated with control of viremia. Science 1997, 278:1447–1450.

    Article  PubMed  CAS  Google Scholar 

  20. Cardo DM, Culver DH, Ciesielski CA, et al.: A case-control study of HIV seroconversion in healthcare workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997, 337:1485–1490.

    Article  PubMed  CAS  Google Scholar 

  21. Mildvan D, Berge P, Starrett S, et al.: Prophylactic zalcitabine and interferon-α for a large-bore needlestick exposure to human immunodeficiency virus. J Acquir Immune Defic Syndr 1994, 7:416–417.

    PubMed  CAS  Google Scholar 

  22. Centers for Disease Control and Prevention. Public Health Service guidelines for the management of healthcare worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 1998, 47 (RR-7): 1–28.

    Google Scholar 

  23. Carpenter CCJ, Cooper DA, Fischl MA, et al.: Antiretroviral therapy in adults; updated recommendations of the International AIDS Society—USA Panel. JAMA 2000, 283:381–390.

    Article  PubMed  CAS  Google Scholar 

  24. Friedland GH, Williams, A: Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999, 13(suppl 1):S61-S72.

    PubMed  Google Scholar 

  25. Mildvan D, Machado SG, Willets I, Grossberg SE: Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992, 339:453–456.

    Article  PubMed  CAS  Google Scholar 

  26. Mildvan D, Ruprecht R, Krown S, Pettinelli C: Application of the combination index method in the design of a clinical antiretroviral trial: ACTG 068. J Acquir Immune Defic Syndr 1990, 3(suppl 2):S111-S113.

    PubMed  Google Scholar 

  27. Mildvan D, Bassiakos Y, Zucker ML, et al.: Synergy, activity, and tolerabili-ty of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068. Antiviral Ther 1996, 1:77–88.

    CAS  Google Scholar 

  28. Gao WY, Shirasaka T, Johns DG, et al.: Differential phosphorylation of azi-dothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993, 91(5):2326–2333.

    Article  PubMed  CAS  Google Scholar 

  29. Shirasaka T, Gao WY, Kojima E, Mitsuya H: Anti-HIV activity of dideoxynu-cleosides in human resting and activated peripheral blood mononuclear cells [abstract Q149]. J Cell Biochem 1993, S17E.

    Google Scholar 

  30. Pollard RB, Peterson D, Hardy D, et al.: Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3. J Acquir Immune Defic Syndr 1999, 22:39–48.

    Article  PubMed  CAS  Google Scholar 

  31. Schuurman R, Nijhuis M, van Leeuwen R, et al.: Rapid changes in human immunodeficiency type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411–1419.

    Article  PubMed  CAS  Google Scholar 

  32. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696–699.

    Article  PubMed  CAS  Google Scholar 

  33. Eron J J, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662–1669.

    Article  PubMed  CAS  Google Scholar 

  34. Haubrich R, Lalezari J, Follansbee SE, et al.: Improved survival and reduced clinical progression in HIV-infected patients with advance disease treated with saquinavir plus zalcitabine. Antivir Ther 1998, 3:33–42.

    CAS  Google Scholar 

  35. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011–1017.

    Article  PubMed  CAS  Google Scholar 

  36. Emini EA: HIV-1 protease inhibitors [abstract LB7]. Presented at the Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, 1996.

    Google Scholar 

  37. Gulick RM, Mellors J, Havlir D, et al.: Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC) [abstract Th.B.931]. Presented at the 11th International Conference on AIDS. Vancouver, BC, 1996.

    Google Scholar 

  38. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N EnglJ Med 1997, 337:734–739.

    Article  CAS  Google Scholar 

  39. Green S, Para MF, Daly PW, et al.: Interim analysis of plasma viral burden reductions and CD4 increases in HIV-1 infected patients with Rescriptor plus Retrovir plus Epivir. 12th World AIDS Conference, Geneva, June 1998, Abstract 129/12219.

    Google Scholar 

  40. Clendenin N, Quart B, Anderson R, et al.: Analysis of long-term virologic data from the Viracept (nelfinavir) 511 trial using 3 HIV-RNA assays. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998, Abstract 372.

    Google Scholar 

  41. Powderly WG, Tebas P: Nelfinavir, a new protease inhibitor: early clinical results. AIDS 1999,13 (suppl 1):S41-S48.

    Article  PubMed  CAS  Google Scholar 

  42. Goodgame J, Hanson C, Vafidis D, Stein A, et al.: Amprenavir/3TC/ZDV is durable and superior to 3TC/ZDV in HIV-infected antiretroviral naïve subjects through 48 weeks. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1999, Abstract 509.

    Google Scholar 

  43. Flexner C:HIV-protease inhibitors. N Engl J Med 1998, 338:1281–1292.

    Article  PubMed  CAS  Google Scholar 

  44. Deeks SG, Hecht FM, Swanson M et al.: HIV-RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999, 13:F35-F43.

    Article  PubMed  CAS  Google Scholar 

  45. Durant P, Clevenbergh P, Halfon P, et al.: Drug-resistant genotyping in HIV-1 therapy: the V1RADAPT randomized controlled trial. Lancet 1999, 353:2195–2199.

    Article  PubMed  CAS  Google Scholar 

  46. Hirsch MS, Conway B, D’Aquila RT, et al.: Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society—USA Panel. JAMA 1998, 279:1984–1991.

    Article  PubMed  CAS  Google Scholar 

  47. Lo JC, Mulligan K, Tai VW, Algren H, et al.: “Buffalo hump” in men with HIV-1 infection. Lancet 1998, 351:867–870.

    Article  PubMed  CAS  Google Scholar 

  48. Miller KD, Jones E, Yanovski JA, et al.: Visceral abdominal fat accumulation associated with the use of indinavir. Lancet 1998, 351:871–875.

    Article  PubMed  CAS  Google Scholar 

  49. Carr A, Samaras K, Thorisdottir A, et al Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipi-demia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093–2099.

    Article  PubMed  CAS  Google Scholar 

  50. Engelson ES, Kotler, DP, Tan Y, et al.: Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 1999, 69:1162–1169.

    PubMed  CAS  Google Scholar 

  51. Mackewicz CE, Ortega HW, Levy JA: CD8+ cell anti-HIV activity correlates * with the clinical state of the infected individual. J Clin Invest 1991, 87:1462–1466.

    Article  PubMed  CAS  Google Scholar 

  52. Jacobson JM, Greenspan JS, Spritzler J, et al.: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997, 336:1487–1493.

    Article  PubMed  CAS  Google Scholar 

  53. Kovacs JA, Baseler M, Dewar RJ, et al.: Increases in CD4+ T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Eng J Med 1995, 332(9):567–575.

    Article  CAS  Google Scholar 

  54. Lori F, Jessen H, Lieberman J, et al.: Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 1999, 180:1827–1832.

    Article  PubMed  CAS  Google Scholar 

  55. Giorgi JV, Ho HN, Hirji I, et al.: CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: Development of HLA-DR+ CD38” CD8+ cells is associated with subsequent stable CD4+ cell levels. J Infect Dis 1994, 170:775–781.

    Article  PubMed  CAS  Google Scholar 

  56. Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune response of human immunodeficiency virus (HlV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321–329.

    Article  PubMed  CAS  Google Scholar 

  57. Li TS, Tubiana R, Katlama C, et al.: Long lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682–1686.

    Article  PubMed  CAS  Google Scholar 

  58. Lederman MM, Connick E, Landay A, et al.: Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998, 178:70 –79.

    Article  PubMed  CAS  Google Scholar 

  59. Connick E, Lederman MM, Kotzin B, et al.: Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologie response. J Infect Dis 2000, 181:358–363.

    Article  PubMed  CAS  Google Scholar 

  60. Paul S, Gilbert HM, Ziecheck W, et al.: The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999, 13:415–418.

    Article  PubMed  CAS  Google Scholar 

  61. Sepkowitz KA. Effect of HAART on natural history of IADS-related opportunistic disorders [comment]. Lancet 1998, 351:228–230.

    Article  PubMed  CAS  Google Scholar 

  62. Centers for Disease Control and Prevention. US AIDS incidence, 1985–1998. Available at: http://www.cdc.gov/hiv/graphics/surveill.htm, January 18, 2000.

  63. Egger M, Hirschel B, Francioli P, et al.: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194–1199.

    Article  PubMed  CAS  Google Scholar 

  64. Ortiz GM, Nixon DF, Trkola A, et al.: HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999, 104:R13-R18.

    Article  PubMed  CAS  Google Scholar 

  65. Lisziewicz J, Rosenberg E, Lieberman J, et al.: Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999, 340:1683–1684.

    Article  PubMed  CAS  Google Scholar 

Selected Bibliography

  • Chiasson MA, Berenson L, Li W, et al.: Declining HIV/AIDS mortality in New York City. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 21:59–64.

    Article  CAS  Google Scholar 

  • Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295–1300.

    Article  PubMed  CAS  Google Scholar 

  • Friedland GH, Williams A: Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999, 13 (suppl 1):S61-S72.

    PubMed  Google Scholar 

  • Gao WY, Shirasaka T, Johns DG, et al.: Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993, 91(5):2326–2333.

    Article  PubMed  CAS  Google Scholar 

  • Kaplan JE, Hanson D, Dworkin MS, et al.: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 30(S1):S5-S14.

    Article  PubMed  Google Scholar 

  • Kaufman D, Pantaleo G, Sudre P, et al.: CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998, 351:723–724.

    Article  Google Scholar 

  • Kovacs JA, Baseler M, Dewar RJ, et al.: Increases in CD4+ T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Eng J Med 1995, 332(9):567–575.

    Article  CAS  Google Scholar 

  • Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696–699.

    Article  PubMed  CAS  Google Scholar 

  • Marschner IC, Collier AC, Coombs RW, et al.: Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998, 177:40–47.

    Article  PubMed  CAS  Google Scholar 

  • Mellors J, Rinaldo CR Jr, Gupta P, et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167–270.

    Article  PubMed  CAS  Google Scholar 

  • Mildvan D, Landay A, DeGruttola V, et al.: An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 1997, 24:764–774.

    Article  PubMed  CAS  Google Scholar 

  • Perelson AS, Neumann AU, Markowitz M, et al.: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582–1586.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Donna Mildvan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Infectious Diseases, University of Virginia Health Sciences Center, Charlottesville, Virginia, USA

    Gerald L. Mandell MD (Professor of Medicine, Owen R. Cheatham Professor of the Sciences, Chief) (Professor of Medicine, Owen R. Cheatham Professor of the Sciences, Chief)

  2. Albert Einstein College of Medicine, Bronx, New York, USA

    Donna Mildvan MD (Professor of Medicine, Chief) (Professor of Medicine, Chief)

  3. Division of Infectious Diseases, Beth Israel Medical Center, New York, New York, USA

    Donna Mildvan MD (Professor of Medicine, Chief) (Professor of Medicine, Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Mildvan, D. (2001). Rationale and Strategies for Antiretroviral Therapy in HIV-1 Infection. In: Mandell, G.L., Mildvan, D. (eds) Atlas of AIDS. Current Medicine Group, London. https://doi.org/10.1007/978-1-4757-4549-8_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-4549-8_19

  • Publisher Name: Current Medicine Group, London

  • Print ISBN: 978-1-4757-4551-1

  • Online ISBN: 978-1-4757-4549-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation